Roschier represented Sedana Medical in connection with its SEK 615 million private placement of new shares
Sedana Medical AB (publ) has completed a directed new share issue, raising proceeds of approximately SEK 615 million. Roschier represented Sedana Medical in connection with the transaction.
The private placement of new shares has been performed through an accelerated book-building procedure carried out by Pareto Securities AB. The private placement was significantly oversubscribed, and a number of Swedish and international institutional and other qualified investors participated in the private placement, including, among others, AMF, Handelsbanken Fonder, Joh. Berenberg, Gossler & Co. KG and Swedbank Robur Fonder.
Sedana Medical is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. The company is listed on Nasdaq First North Growth Market and headquartered in Stockholm, Sweden.
Roschier’s advisory team comprised Christoffer Benninge, Linnea Björkstrand and Noah Taha from our Equity Capital Markets practice.